Publication Name	World Journal of Clinical Oncology
Manuscript ID	61561
Country	Saudi Arabia

Received	2020-12-22 07:57
Peer-Review Started	2020-12-22 07:58
To Make the First Decision
Return for Revision	2021-01-11 03:28
Revised	2021-01-30 06:47
Second Decision	2021-02-25 06:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-08 03:49
Articles in Press	2021-03-08 03:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-06 02:42
Publish the Manuscript Online	2021-04-20 12:49

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Case Report
Article Title	Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Muhammad Imran Butt, Abdulmohsen Mohammed Khalid Bakhsh and Quaid Johar Nadri
ORCID	Author(s) ORCID Number Muhammad Imran Butt http://orcid.org/0000-0002-2143-7303 Abdulmohsen Mohammed Khalid Bakhsh http://orcid.org/0000-0003-3881-0300 Quaid Johar Nadri http://orcid.org/0000-0002-6654-4196
Funding Agency and Grant Number
Corresponding Author	Muhammad Imran Butt, FRCP, MD, MRCP, Doctor, Department of Medicine, King Faisal Specialist Hospital, Research Centre, Al Faisal University, Zahrawi St, Al Maather, Al Maazer, Riyadh 12713, Saudi Arabia. mimran74@hotmail.com
Key Words	Hurthle cell thyroid cancer; Lenvatinib; Nephrotic syndrome; Vascular endothelial growth factor; Protein kinase inhibitors; Kidney neoplasms/secondary neoplasm; Case report
Core Tip	The present case study provides a unique learning and case management experience. Our patient had widespread metastasis from a histopathologically low-risk thyroid cancer coupled with two decades of survival despite noniodine-avid metastasis, treatment of renal metastasis with tyrosine kinase inhibitors, and the development of multisystem adverse events, including rare nephrotic syndrome.
Publish Date	2021-04-20 12:49
Citation	Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report . World J Clin Oncol 2021; 12(4): 272-281
URL	https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i4.272

Full Article (PDF)	WJCO-12-272.pdf
Full Article (Word)	WJCO-12-272.docx
Manuscript File	61561_Auto_Edited_LM.docx
Answering Reviewers	61561-Answering reviewers.pdf
Audio Core Tip	61561-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	61561-Conflict-of-interest statement.pdf
Copyright License Agreement	61561-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	61561-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	61561-Language certificate.pdf
Peer-review Report	61561-Peer-review(s).pdf
Scientific Misconduct Check	61561-Bing-Wang JL-1.jpg
Scientific Misconduct Check	61561-Scientific misconduct check.pdf
Scientific Editor Work List	61561-Scientific editor work list.pdf